Camlin Fine Sciences Limited (NSE:CAMLINFINE)
India
· Delayed Price · Currency is INR | Market Cap | 55.11B |
| Revenue (ttm) | 16.67B |
| Net Income (ttm) | -1.39B |
| Shares Out | n/a |
| EPS (ttm) | -7.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 287,647 |
| Average Volume | 709,009 |
| Open | 290.70 |
| Previous Close | 293.80 |
| Day's Range | 286.60 - 301.00 |
| 52-Week Range | 95.59 - 333.30 |
| Beta | 0.50 |
| RSI | 52.44 |
| Earnings Date | Aug 4, 2025 |
About Camlin Fine Sciences
Camlin Fine Sciences Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of specialty chemicals, ingredients, and additive blend products in India and internationally. The company offers shelf-life solutions, which include antioxidants comprises Butylated Hydroxy Toluene and Ascorbyl palmitate; and emulsifiers, mold inhibitors, antibacterial agents, toxin binders, pellet binders, disinfectants, energizers, preservatives, thickening agents, and growth promoters, as well as plant-based antioxi... [Read more]
Financial Performance
In 2024, Camlin Fine Sciences's revenue was 16.67 billion, an increase of 3.31% compared to the previous year's 16.13 billion. Losses were -1.39 billion, 49.9% more than in 2023.
Financial StatementsNews
Camlin Fine Sciences Q3 FY25 results: Revenue rises 8.7% YoY to Rs 435.5 crore, net loss at Rs 158.2 crore
The company attributed the net loss to several factors, including impairments on overseas subsidiaries, non-cash adjustments, and foreign exchange losses.
Top stocks to buy today: Stock recommendations for February 7, 2025
Stock market recommendations: Bajaj Broking Research recommends buying Camlin Fine Sciences and Equinox India Developments for favorable stock positions. The Nifty is expected to sustain a positive bi...